For Patients with Multiple Myeloma, DTP3 May Be Effective
the Cancer Therapy Advisor take:
According to a study published in the journal Cancer Cell, researchers at Imperial College London in London, United Kingdom, have developed a novel cancer drug called DTP3 that has effectively killed myeloma cells in human cells and mice during laboratory tests. The drug did not cause any toxic adverse effects, a common problem with most other anticancer drugs. DTP3 works by inhibiting an important process involved with cancer cell proliferation.
By studying cancer cells from patients with multiple myeloma, the researchers identified GADD45β/MKK7, a protein complex that plays a key role in helping cancer cells to survive.
By targeting this protein complex with DTP3, the nuclear factor kappa B (NF-kB) signaling pathway, which is overactive in numerous types of cancer and responsible for preventing apoptosis, becomes interrupted, thereby leading to selective myeloma cell death. A key benefit of DTP3 is that it does not result in toxic side effects at the doses that have destroyed tumors in mice.
The researchers are optimistic that DTP3 could have therapeutic benefit for the treatment of patients with multiple myeloma and possibly other types of cancer. They hope to begin clinical trials next year.
A novel cancer drug called DTP3 has effectively killed myeloma cells in human cells.
Scientists at Imperial College London have developed a new cancer drug which they plan to trial in multiple myeloma patients by the end of next year. In a paper published today in the journal Cancer Cell, the researchers report how the drug, known as DTP3, kills myeloma cells in laboratory tests in human cells and mice, without causing any toxic side effects, which is the main problem with most other cancer drugs.
The new drug works by stopping a key process that allows cancer cells to multiply. The team have been awarded Biomedical Catalyst funding from the Medical Research Council (MRC) to take the drug into a clinical trial in multiple myeloma patients, scheduled to begin in late 2015. Multiple myeloma is an incurable cancer of the bone marrow, which accounts for nearly two per cent of all cancer deaths.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Apalutamide Does Not Diminish Quality of Life in Nonmetastatic Castration-Resistant Prostate Cancer
- Treatment Delays May Mean Worse Survival in Head and Neck Cancer
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Emetogenic Potential of Antineoplastic Agents
- Combination Abiraterone Acetate, Radium-223 Not Recommended in CRPC With Bone Mets
- Brigatinib Found More Effective for ALK-positive NSCLC Brain Mets Compared With Crizotinib
- Higher Baseline AFP Linked to Greater Benefit With Cabozantinib in Hepatocellular Carcinoma
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- A Big BiTE: Tetravalent BiTE Highly Potent in HER2-positive Breast Cancer Models